Abstract:
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that its novel drug delivery platform, BioSilicon(TM) has demonstrated the capability to act as an adjuvant when delivered with an antigen.